Clinical Trial

First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer

Study acronym: RCTS
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, single arm, multicenter phase II study aimed at evaluating the efficacy and safety of Disitamab Vedotin in Combination With Tirelizumab and S-1 as first-line treatment for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-10-16; most recent amendment 2025-02-05.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-01-05
Trial Details
NCT Number NCT05586061
Lead Sponsor Qilu Hospital of Shandong University
Conditions HER2-positive Gastric Cancer
Enrollment 55 participants
Start Date 2023-02-10
Primary Completion 2024-12-29 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-07